These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 23218491)

  • 1. Words of wisdom. Re: Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation: analysis of trends over time.
    Catalona WJ
    Eur Urol; 2013 Jan; 63(1):179. PubMed ID: 23218491
    [No Abstract]   [Full Text] [Related]  

  • 2. Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation: analysis of trends over time.
    Scosyrev E; Wu G; Mohile S; Messing EM
    Cancer; 2012 Dec; 118(23):5768-76. PubMed ID: 22847578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of prostate-specific antigen screening on metastatic disease burden 10 years after diagnosis.
    Ciezki JP; Reddy CA; Kupelian PA; Klein EA
    Urology; 2012 Aug; 80(2):367-72. PubMed ID: 22857756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Words of wisdom. Re: Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer.
    Thalmann GN
    Eur Urol; 2009 Nov; 56(5):884-5. PubMed ID: 20965034
    [No Abstract]   [Full Text] [Related]  

  • 5. Words of wisdom. Re: Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era.
    Shteynshlyuger A; Kibel AS
    Eur Urol; 2009 Dec; 56(6):1089-90. PubMed ID: 20965041
    [No Abstract]   [Full Text] [Related]  

  • 6. Words of wisdom. Re: Combining 33 genetic variants with prostate-specific antigen for the prediction of prostate cancer: longitudinal study.
    Ankerst DP; Thompson IM
    Eur Urol; 2012 Jul; 62(1):180. PubMed ID: 22640856
    [No Abstract]   [Full Text] [Related]  

  • 7. Words of wisdom. Re: Quality-of-life effects of prostate-specific antigen screening.
    Catalona WJ
    Eur Urol; 2013 Jan; 63(1):180. PubMed ID: 23218492
    [No Abstract]   [Full Text] [Related]  

  • 8. Screening with prostate specific antigen and metastatic prostate cancer risk: a population based case-control study.
    Kopec JA; Goel V; Bunting PS; Neuman J; Sayre EC; Warde P; Levers P; Fleshner N
    J Urol; 2005 Aug; 174(2):495-9; discussion 499. PubMed ID: 16006879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Words of Wisdom. Re: prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.
    Terrone C
    Eur Urol; 2011 Feb; 59(2):304-5. PubMed ID: 21414880
    [No Abstract]   [Full Text] [Related]  

  • 10. Words of wisdom. Re: Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program.
    Bastian PJ
    Eur Urol; 2010 Nov; 58(5):796. PubMed ID: 21414861
    [No Abstract]   [Full Text] [Related]  

  • 11. Words of wisdom. Re: Quality-of-life effects of prostate-specific antigen screening.
    Cooperberg MR
    Eur Urol; 2013 Jun; 63(6):1130. PubMed ID: 23608080
    [No Abstract]   [Full Text] [Related]  

  • 12. Words of wisdom: Re: Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States.
    Vickers A
    Eur Urol; 2011 Aug; 60(2):392. PubMed ID: 21703965
    [No Abstract]   [Full Text] [Related]  

  • 13. Words of wisdom. Re: Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up.
    Vickers A
    Eur Urol; 2012 Aug; 62(2):353. PubMed ID: 22748397
    [No Abstract]   [Full Text] [Related]  

  • 14. Words of wisdom. Re: copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer.
    Marks LS; Huang J
    Eur Urol; 2010 Apr; 57(4):727-8. PubMed ID: 20965042
    [No Abstract]   [Full Text] [Related]  

  • 15. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
    Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
    Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival.
    Cheville JC; Tindall D; Boelter C; Jenkins R; Lohse CM; Pankratz VS; Sebo TJ; Davis B; Blute ML
    Cancer; 2002 Sep; 95(5):1028-36. PubMed ID: 12209687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in prostate cancer incidence and mortality: an analysis of mortality change by screening intensity.
    Coldman AJ; Phillips N; Pickles TA
    CMAJ; 2003 Jan; 168(1):31-5. PubMed ID: 12515782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Words of wisdom. Re: Abiraterone and increased survival in metastatic prostate cancer.
    Cheetham PJ; Petrylak DP
    Eur Urol; 2012 Apr; 61(4):850. PubMed ID: 22373884
    [No Abstract]   [Full Text] [Related]  

  • 19. Words of wisdom. Re: Abiraterone and increased survival in metastatic prostate cancer.
    Richie JP
    Eur Urol; 2011 Oct; 60(4):871. PubMed ID: 21878199
    [No Abstract]   [Full Text] [Related]  

  • 20. Words of wisdom. Re: Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening.
    Taneja SS
    Eur Urol; 2007 Aug; 52(2):607. PubMed ID: 17674442
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.